5.JPM2026隐含大药机遇详细梳理，积极布局医药底部资产

5. JPM 2026 隐含大药机遇详细梳理；积极布局医药底部资产 | 增持（维持） 评级： | | | 重点公司基本状况 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | 分析师：祝嘉琦 | | | （元） | 2023A | 2024A | 2025E | 2026E | 2027E | 2023A | 2024A | 2025E | 2026E | 2027E | | | 执业证书编号：S0740519040001 | | 药明生物 | 37.68 | - | - | 0.96 | 1.17 | 1.47 | - | | - 39.34 | 32.20 | 25.69 | 买入 | | Email：zhujq@zts.com.cn | | 泰格医药 | 65.65 | 2.34 | 0.47 | 1.25 | 1.47 | 1 ...